| Elizabeth Stryker, DPT | |
|
180 Mount Airy Rd Ste 130, Basking Ridge, NJ 07920-2064 | |
| (908) 766-1407 | |
| Not Available |
| Full Name | Elizabeth Stryker |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 16 Years |
| Location | 180 Mount Airy Rd Ste 130, Basking Ridge, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366813255 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 40QA01636100 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Riverwalk Physical Therapy, Llc | 1557545308 | 10 |
News Archive
Spanish researchers have studied adults' accuracy in the recognition of the emotion causing babies to cry. Eye movement and the dynamic of the cry play a key role in recognition.
TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
VENITI, Inc., a St. Louis, MO-based medical device company is pleased to announce that it has closed on an equity and debt financing totaling over $17 million. The equity portion, its Series C, was led by previous investors, Baird Capital and Tekla Healthcare and Tekla Life Science Investors, with strong internal participation.
AstraZeneca and EvoRx Technologies successfully completed a one-year research collaboration leveraging EvoRx's proprietary Evo-Link technology to discover cell penetrating peptides for a high value intracellular protein–protein interaction target in the respiratory portfolio.
Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.
› Verified 5 days ago
| Provider Name | Riverwalk Physical Therapy, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1750681201 PECOS PAC ID: 1557545308 Enrollment ID: O20110404000144 |
News Archive
Spanish researchers have studied adults' accuracy in the recognition of the emotion causing babies to cry. Eye movement and the dynamic of the cry play a key role in recognition.
TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
VENITI, Inc., a St. Louis, MO-based medical device company is pleased to announce that it has closed on an equity and debt financing totaling over $17 million. The equity portion, its Series C, was led by previous investors, Baird Capital and Tekla Healthcare and Tekla Life Science Investors, with strong internal participation.
AstraZeneca and EvoRx Technologies successfully completed a one-year research collaboration leveraging EvoRx's proprietary Evo-Link technology to discover cell penetrating peptides for a high value intracellular protein–protein interaction target in the respiratory portfolio.
Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Stryker, DPT 41 Pill Hill Rd, Bernardsville, NJ 07924-2807 Ph: (610) 996-5130 | Elizabeth Stryker, DPT 180 Mount Airy Rd Ste 130, Basking Ridge, NJ 07920-2064 Ph: (908) 766-1407 |
News Archive
Spanish researchers have studied adults' accuracy in the recognition of the emotion causing babies to cry. Eye movement and the dynamic of the cry play a key role in recognition.
TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
VENITI, Inc., a St. Louis, MO-based medical device company is pleased to announce that it has closed on an equity and debt financing totaling over $17 million. The equity portion, its Series C, was led by previous investors, Baird Capital and Tekla Healthcare and Tekla Life Science Investors, with strong internal participation.
AstraZeneca and EvoRx Technologies successfully completed a one-year research collaboration leveraging EvoRx's proprietary Evo-Link technology to discover cell penetrating peptides for a high value intracellular protein–protein interaction target in the respiratory portfolio.
Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.
› Verified 5 days ago
Dr. Marc Francis Riccardi, DPT Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 150 N Finley Ave, Basking Ridge, NJ 07920 Phone: 908-340-4772 Fax: 908-340-4774 | |
Maryl R. Wilensky, M.S.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 180 Mount Airy Rd 103, Basking Ridge, NJ 07920 Phone: 908-766-1407 | |
Joseph John Biland, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 180 Mount Airy Rd, Basking Ridge, NJ 07920 Phone: 908-766-1407 | |
Action Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 413 King George Rd, Suite 204, Basking Ridge, NJ 07920 Phone: 908-903-0100 | |
Angelica Borja, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 552 Allen Rd, Basking Ridge, NJ 07920 Phone: 908-605-0125 | |
Sarah Elissa Cwiak, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 404 King George Rd, Basking Ridge, NJ 07920 Phone: 908-647-3206 Fax: 908-647-3206 | |
Peter Woghiren, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 25 Mountainview Blvd Ste 207, Basking Ridge, NJ 07920 Phone: 908-758-1006 Fax: 908-360-0511 |